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OBJECTIVES This study was designed to determine if aspirin resistance is associated with clinical events.
BACKGROUND Aspirin resistance, defined by platelet function testing and presumed clinical unresponsiveness
to aspirin, has been previously reported by our group and others. However, little information
exists linking the laboratory documentation of aspirin resistance and long-term clinical events.
METHODS We prospectively enrolled 326 stable cardiovascular patients from 1997 to 1999 on aspirin
(325 mg/day for 7 days) and no other antiplatelet agents. We tested for aspirin sensitivity
by optical platelet aggregation using adenosine diphosphate (ADP) and arachidonic acid
(AA). The primary outcome was the composite of death, myocardial infarction (MI), or
cerebrovascular accident (CVA). Mean follow-up was 679 185 days. Aspirin resistance was
defined as a mean aggregation of 70% with 10 M ADP and 20% with 0.5 mg/ml AA.
RESULTS Of the patients studied, 17 (5.2%) were aspirin resistant and 309 (94.8%) were not aspirin
resistant. During follow-up, aspirin resistance was associated with an increased risk of death,
MI, or CVA compared with patients who were aspirin sensitive (24% vs. 10%, hazard ratio
[HR] 3.12, 95% confidence interval [CI] 1.10 to 8.90, p  0.03). Stratified multivariate
analyses identified platelet count, age, heart failure, and aspirin resistance to be independently
associated with major adverse long-term outcomes (HR for aspirin resistance 4.14, 95% CI
1.42 to 12.06, p  0.009).
CONCLUSIONS This study demonstrates the natural history of aspirin resistance in a stable population,
documenting a greater than threefold increase in the risk of major adverse events associated
with aspirin resistance. (J Am Coll Cardiol 2003;41:961–5) © 2003 by the American
College of Cardiology Foundation
Aspirin is the cornerstone of antiplatelet therapy in cardio-
vascular medicine today. It exerts its antiplatelet effect by
acetylation of the platelet cyclooxygenase, resulting in an
irreversible inhibition of platelet-dependent thromboxane
formation (1). In their most recent meta-analysis of more
than 200,000 patients from 287 randomized trials, the
Antithrombotic Trialists’ Collaboration has documented
the powerful effect of aspirin in reducing ischemic vascular
events by 22% compared with control in a wide array of
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atherothrombotic conditions (2). However, aspirin has been
shown to have variable antiplatelet activity in individual
patients. Previous studies have estimated that 5% to 45% of
the population do not achieve an adequate antiplatelet effect
from aspirin (3–7). Little prospective data are available for
extended long-term follow-up of stable patients concerning
the clinical consequences of aspirin resistance.
In a cohort of 326 stable cardiovascular patients, we
previously demonstrated approximately 1 in 20 has labora-
tory evidence of aspirin resistance as measured by optical
platelet aggregation (3). We used this prospectively col-
lected population of patients to determine the long-term
clinical significance of aspirin resistance.
METHODS
Study group. We prospectively enrolled 326 stable cardio-
vascular patients between January 1997 and September
1999. The patients were recruited from consecutive patients
presenting to the outpatient clinic or for elective cardiac
catheterization. All patients had prior history of cardiovas-
cular disease as defined by previous documented coronary
stenosis on cardiac catheterization of 60%, previous his-
tory of myocardial infarction (MI) or stroke, or previous
invasive cardiovascular revascularization procedure. The
study was reviewed and approved by the Institutional
Review Board. All participants gave informed consent
before enrollment. We evaluated these patients for labora-
tory evidence of aspirin resistance. Patients who were 21
years old and taking 325 mg of aspirin for 7 days
immediately before were eligible for enrollment. Compli-
ance on aspirin was determined by patient interview both at
study enrollment and follow-up. Exclusion criteria included:
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ingestion of ticlopidine, dipyridamole, or other nonsteroidal
anti-inflammatory drugs; use of other drugs containing
aspirin; administration of heparin or low-molecular-weight
heparin within 24 h before enrollment; major surgical
procedure within one week before enrollment; malignant
paraproteinemias; family or personal history of bleeding
disorders; platelet count150 103/l or450 103/l;
hemoglobin 8g/dl, history of myeloproliferative disorders;
or history of heparin-induced thrombocytopenia.
Blood samples. Four samples of whole blood were col-
lected in 3.8% sodium citrate for platelet aggregation
testing. One tube of blood anticoagulated with ethylenedia-
minetetraacetic acid was collected for baseline hemoglobin
and platelet count. The last dose of aspirin was administered
within 1 to 24 h before blood sampling. Room-temperature
blood samples were processed within 1 h of blood collection.
Whole-blood specimens were centrifuged for 10 min at
200 g to obtain platelet-rich plasma. Platelet-poor plasma
was obtained on the remaining specimen by re-
centrifugation at 2,000 g for 15 min. A platelet count was
measured on the platelet-rich plasma and was adjusted to
between 200 103/l and 300 103/l with platelet-poor
plasma. The baseline optical density was set with platelet-
poor plasma. Aggregation was performed using adenosine
5-diphosphate (ADP) (BioData, Horsham, Pennsylvania)
at 10 M and arachidonic acid (AA) at 0.5 mg/ml with a
BioData PAPS-4 platelet aggregometer (BioData).
For optical platelet aggregation, optical density changes
were detected photoelectrically as platelets began to aggre-
gate. Adenosine diphosphate promotes the release of en-
dogenous ADP and thromboxane A2 when added to
platelet-rich plasma, causing irreversible aggregation. The
test is abnormal in patients using aspirin or having aspirin-
like release defects, storage pool disease, afibrinogenemia, or
Glanzmann’s thrombasthenia. Arachidonic acid is used to
evaluate the degree of inhibition of platelet aggregation by
aspirin. The addition of AA to platelet-rich plasma en-
hances platelet aggregation by producing thromboxane A2.
The test is abnormal in patients using aspirin, having
aspirin-like release defects, and Glanzmann’s thrombasthe-
nia. Aspirin resistance was defined as a mean aggregation of
70% with 10 M ADP and a mean aggregation of 20%
with 0.5 mg/ml AA. Laboratory norms were established by
screening 40 in-house normal samples.
Study end points. The primary end point was the com-
posite of death, MI, or cerebrovascular accident (CVA).
Secondary end points were the individual events of death,
MI, and CVA. Death was defined as all-cause mortality due
to MI, ischemic CVA, and other vascular and nonvascular
causes. Myocardial infarction was defined as the presence of
at least two of these criteria: prolonged angina 30 min;
total creatinine kinase elevation 2 times the upper limit of
normal as confirmed by creatine kinase-MB fraction isoen-
zyme elevation; electrocardiogram evidence of infarction,
defined as ST-segment elevation of at least 0.1 mV (mea-
sured 0.2 s after the J-point) in two contiguous leads; or new
significant Q-wave of 0.04 s duration or having a depth
greater than one-fourth of the corresponding R-wave am-
plitude, or both. Cerebrovascular accident was defined as an
acute neurologic vascular event with focal signs for more
than 24 h.
Follow-up. Follow- up was performed by telephone inter-
view and query of the Social Security Death Index on all
patients enrolled regardless of aspirin resistance status be-
tween November 2000 and June 2001. Persons performing
follow-up interviews were blind to aspirin sensitivity status.
For those patients having reached at least one of the primary
end points, a medical chart review was initiated to deter-
mine whether the event met the definitions described.
Follow-up was complete on 96.9% of all patients enrolled.
Of those determined to be aspirin resistant, follow-up was
complete on 94.1%, and of those determined to not be
aspirin resistant, follow-up was complete on 97.1%.
Follow-up via telephone and chart review was complete on
293 patients and data concerning death were retrieved solely
via the Social Security Death Index on 23 patients.
Statistical analysis. Categorical variables are presented as
frequencies and percentages. For the categorical variables,
patient demographics between groups were compared using
chi-square tests or, if expected cell frequencies were small,
exact tests. Continuous variables are presented as means 
SD. The p values associated with continuous variables were
generated by Wilcoxon two-sample tests (because the fac-
tors were not normally distributed). Kaplan-Meier product
limits were computed for freedom from death, MI, CVA,
and the primary end point of composite death, MI, or CVA
with respect to aspirin resistance status. Log-rank tests were
used for screening univariable group results with respect to
outcomes. Cox proportional modeling techniques were used
to describe the risks for the composite end point of death,
MI, or CVA. Variables entered into the model include: age,
gender, race, history of tobacco use, diabetes, hypertension,
hyperlipidemia, revascularization, MI, hemoglobin, platelet
count, creatinine, and aspirin sensitivity.
RESULTS
Patient characteristics. Of the 326 patients enrolled,
follow-up was available on 315 (97%). Mean follow-up was
679 days. Baseline characteristics comparing the two
groups, aspirin resistant versus not aspirin resistant, are
presented in Table 1. Of the 326 patients studied, 17 (5.2%)
were aspirin resistant by optical aggregation. Patients who
Abbreviations and Acronyms
AA  arachidonic acid
ADP  adenosine diphosphate
CI  confidence interval
CVA  cerebrovascular accident
HR  hazard ratio
MI  myocardial infarction
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were aspirin resistant were more likely to be women and had
a slightly lower hemoglobin count compared with patients
who were not aspirin resistant. The two groups had similar
rates of previous cardiovascular events, including history of
prior revascularization procedures, MIs, or neurologic
events. Classic atherosclerotic risk factors were similar
between the two groups.
Additional medication use both at baseline and during
follow-up was not significantly different between the two
groups. Of the patients documented at baseline to be aspirin
resistant, 12% discontinued aspirin for 1 month during
follow-up compared with 8% of those documented to be
aspirin sensitive (p  0.6). Use of medications well proven
to reduce clinical events by other previous studies, including
beta-blockers, angiotensin-converting enzyme inhibitors,
statins, and thienopyridine inhibitors, was similar between
the two groups as well.
Clinical events. Major events occurred in 34 (10%) of the
326 patients. Among the patients who were aspirin resis-
tant, 4 of 17 (24%) experienced death, MI, or CVA,
compared with 30 of 309 (10%) patients who were not
aspirin resistant (p  0.03). Hazard ratios (HRs) for both
univariate and multivariate analyses are outlined in Table 2.
Patients who were aspirin resistant were more likely to
experience a major clinical event compared with patients
who were not aspirin resistant. Although the association for
aspirin resistance and adverse individual outcomes did not
reach statistical significance, there was a consistent unfavor-
able trend associated with aspirin resistance for these end
points as well (death 12% aspirin resistant vs. 5% not aspirin
resistant, p  0.13, MI 7% aspirin resistant vs. 4% not
aspirin resistant, p  0.54, and CVA 12% aspirin resistant
vs. 1% not aspirin resistant, p  0.09). Figure 1 depicts the
Kaplan-Meier time-to-event curves for event-free survival
based on aspirin sensitivity with log-rank test results. After
adjustment for other clinical factors, aspirin resistance re-
mained an independent predictor of long-term adverse
events (HR 4.14, 95% confidence interval [CI] 1.42 to
12.06), p  0.009). Other factors identified as correlates of
poor outcome were history of congestive heart failure,
elevated platelet count, and increasing age.
Although the primary purpose of this study sought to







(n  309) p Value
Clinical factors
Age, mean  SD (yrs) 59  15 62  11 0.4
Female (%) 8 (47) 65 (21) 0.03
Tobacco use (%) 0 (0) 19 (6) 0.6
Diabetes (%) 3 (18) 77 (25) 0.8
Prior CABG (%) 7 (41) 111 (36) 0.6
Prior PCI (%) 4 (24) 105 (34) 0.4
Prior MI (%) 5 (29) 118 (38) 0.5
Prior CVA (%) 1 (6) 15 (5) 0.4
CHF (%) 0 (0) 17 (6) 1.0
Laboratory values
Hemoglobin (g/dl) 13  2 14  2 0.02
Platelet count ( 103/l) 223  69 217  68 0.9
Medication use baseline
-blocker (%) 8 (47) 162 (52) 0.9
ACE inhibitor (%) 7 (41) 121 (39) 0.7
Statin (%) 8 (47) 166 (54) 0.6
Medication use follow-up
No ASA for 1 month (%) 2 (12) 24 (8) 0.6
-blocker (%) 10 (59) 160 (52) 0.5
ACE inhibitor (%) 7 (42) 116 (38) 0.8
Statin (%) 9 (53) 186 (60) 0.5
Ticlopidine/clopidogrel (%) 2 (12) 10 (3) 0.1
ACE  angiotensin-converting enzyme; ASA  aspirin; CABG  coronary artery
bypass grafting; CHF  congestive heart failure; CVA  cerebrovascular accident;
MI  myocardial infarction; PCI  percutaneous coronary intervention.
Table 2. Analyses of Time-to-Event Among Patients According
to Aspirin Sensitivity
HR (95% CI) p Value
Univariate analyses
Death/MI/CVA 3.12 (1.10–8.90) 0.03
Death 2.98 (0.68–13.14) 0.15
MI 1.91 (0.25–14.72) 0.54
CVA 5.44 (0.60–49.49) 0.13
Multivariate analyses
Aspirin resistant 4.14 (1.42–12.06) 0.009
Age 1.05 (1.02–1.08) 0.003
Platelet count 1.01 (1.00–1.01)  0.001
History of CHF 3.04 (1.15–8.03) 0.025
CI  confidence interval; HR  hazard ratio. Other abbreviations as in Table 1.
Figure 1. Time-to-event curves, log rank chi-square  5.05, p  0.03.
CVA  cerebrovascular accident; MI  myocardial infarction.
Figure 2. Events (death, myocardial infarction, or cerebrovascular acci-
dent) by mean percent platelet aggregation with adenosine diphosphate
(ADP).
963JACC Vol. 41, No. 6, 2003 Gum et al.
March 19, 2003:961–5 The Natural History of Aspirin Resistance
evaluate clinical risk associated with a predefined set point
of platelet aggregation despite aspirin therapy, we further
evaluated events on a continuous basis. Figure 2 depicts all
events (death, MI, or CVA) in relation to the mean percent
platelet aggregation with ADP. Although the results do not
reach statistical significance, a distinct gradation of in-
creased risk for clinical events with increased platelet aggre-
gation despite aspirin therapy can be seen.
DISCUSSION
In this blinded, prospective study, we demonstrated aspirin
resistance as documented by optical platelet aggregation
testing to be negatively associated with long-term outcomes
in a population of stable cardiovascular patients. Previous
studies have demonstrated aspirin resistance by both clinical
evidence of unresponsiveness to aspirin (8) and ex vivo
platelet function testing (5,9–13). To date only three studies
have evaluated the clinical consequence of aspirin resistance
in select populations (14–16). Grotemeyer et al. (14)
evaluated 180 acute stroke patients for evidence of aspirin’s
effect on platelet reactivity. Patients with elevated platelet
reactivity despite aspirin were more likely to experience
vascular death, MI, or CVA. Mueller et al. (15) reported an
association between failed inhibition of platelet reactivity by
aspirin and risk of reocclusion after peripheral vascular
angioplasty in patients with claudication. Most recently,
Eikelboom et al. (16) reported an increased risk for MI, CVA,
or cardiovascular death associated with aspirin resistance as
documented by urinary concentrations of 11-dehydro throm-
boxane B2 in patients with cardiovascular disease or diabetes
and one other risk factor for cardiovascular disease.
The current study extends these previous findings in
several important respects. Our study was performed in a
prospective, blinded fashion. Those performing the optical
aggregation testing were blind to clinical histories, and
follow-up was done in a blinded manner without regard to
aspirin sensitivity. We prospectively set out to measure the
incidence of aspirin resistance in a stable population and to
determine its clinical significance. We utilized optical plate-
let aggregation, the current gold standard of platelet aggre-
gation, to measure aspirin resistance. We established normal
values via 40 in-house normal samples. With respect to
clinical significance, we used “real-world” end points, in-
cluding all-cause mortality, MI, and CVA, rather than
vascular death or vessel reocclusion. Furthermore, this study
evaluated the clinical significance of aspirin resistance in a
stable cardiovascular population that had not experienced a
recent acute event before enrollment. The natural history of
aspirin resistance has not previously been evaluated in this
population in a fully prospective manner.
Recent trials have demonstrated the superior clinical
benefit of clopidogrel and the combination of clopidogrel
with aspirin compared with aspirin alone (17–19). These
studies make it apparent that alternative antiplatelet agents
will likely play a significant role in the treatment of
cardiovascular disease. It is plausible that the clinical benefit
of clopidogrel and agents similar to it observed in these trials
would be even more pronounced in patients who are aspirin
resistant and therefore not benefiting from adequate anti-
platelet inhibition. Thus, future treatment of aspirin resis-
tance with additional antiplatelet agents such as clopidogrel
may significantly improve the poor prognosis we found
associated with this diagnosis.
The late divergence of the event curves that we observed
is intriguing. It is not entirely clear why this occurred. That
our patient population was composed of patients who were
clinically stable upon enrollment and therefore less likely to
have acute events during early follow-up may have influ-
enced the timing of events. Alternatively, the small number
of patients enrolled may have contributed to skewing the
curves. This clinical finding needs to be further investigated
with additional, larger trials.
There remain other significant areas in this field that need
further investigation. The findings of our study should be
confirmed with larger trials in various populations. Al-
though possible explanations of aspirin resistance include
the presence of PlA2 polymorphism, degree of
cyclooxygenase-2 expression, and the role of erythrocytes,
the definitive mechanism of aspirin resistance has not yet
been elucidated. This will ultimately be important to
allow prospective diagnosis of aspirin resistance, which
will help guide the selection of antiplatelet therapy as well
as potential pharmacogenomic therapy. Likewise, clinical
studies evaluating the possible benefit from alternative
antiplatelet agents in aspirin-resistant patients will be
important. Finally, the possibility of thienopyridine re-
sistance also warrants investigation.
Study limitations. There are some inherent limitations to
our study. Aspirin use was based on answers to question-
naires. Salicylate levels or pill counts were not performed.
Aggregation studies were performed only at baseline, and it
is possible that response to aspirin is variable. Although our
study demonstrated an association between aspirin resis-
tance and long-term clinical events, the overall number of
events is small. Our estimate of the clinical consequences of
aspirin resistance may therefore be under- or overestimated.
Conclusions. Aspirin resistance is an important and real
clinical diagnosis. Our study demonstrates it to be signifi-
cantly associated with major adverse events during long-
term follow-up. The availability of safe, alternative long-
term antiplatelet agents makes screening for aspirin resistance
in cardiovascular patients a potentially important and useful
diagnostic test. Further investigation to confirm our findings,
evaluate possible treatments, and elucidate the precise biologic
mechanism of aspirin resistance should be performed.
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